York Pharma acquires, develops and markets dermatology treatments. Its original product was Abasol, which had been developed up to phase III trials by a major European company, and is a treatment for fungal infections. York joined Aim on 26 April 2004, when it raised £1m gross (£735,000 net) via a placing and offer for subscription at 25p a share. It started out as a shell formed by Reverse Takeover Investments, a subsidiary of Aim-quoted Westside Acquisitions. In December 2004, it raised a further £2.8m at 80p a share. In early 2005, York bought Molecular Skincare for shares and it brought with it £2m in cash. It also expanded the range of products into eczema and psoriasis. In July 2005, sphingosine-1-phosphate, an acne treatment was acquired. In April 2007, York acquired Rosanto Pharmaceuticals for £2m in shares at a notional price of 123.7p a share. At the same time a placing at 120p a share raised £5.25m gross. In November 2007, York paid up to £17.5m in shares for Derms Development in order to benefit from its sales force in the UK and France. At the same time York raised £5.35m at 120p a share. In July 2008, York acquired Flammazine and Flammacerium from Solvay Pharmaceuticals for £22.6m. It was financed by loan notes and a £3.9m placing at 44p a share.